Clinical trials: Clopidogrel
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Stroke, Transient Ischemic Attack
International PFO Consortium
The prevalence of patent foramen ovale (PFO) is about 25% in the general population and approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke).
- Trial name
- NCT00859885
- Testing
- Antithrombotic treatment, percutaneous device closure of PFO
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 1,500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Healthy
Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects
Effects of clopidogrel and clarithromycin on the oral disposition of sibutramine in healthy subjects
- Trial name
- sibu (NCT01421706)
- Testing
- Sibutramine-clopidogrel, sibutramine-Clarithromycin
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Inje University
Ischemic Stroke
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed…
- Trial name
- NCT06591338
- Testing
- Ticagrelor 90 MG, Clopidogrel, Aspirin 75 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
ICAS - Intracranial Atherosclerosis
IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)
A multicenter, open-label, blinded-endpoint, prospective, randomized controlled clinical trial with an "all comers" design.
- Trial name
- NCT05974033
- Testing
- Stenting plus medical therapy, Medical therapy alone
- Volunteers
- 536 people
- Sponsor
- Changhai Hospital
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)
The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation therapy with a lower risk of bleeding in…
- Trial name
- NCT00243178
- Testing
- clopidogrel (SR25990C)
- Where
- 32 sites in United States, Australia and 30 more
- Volunteers
- 6,706 people
- Sponsor
- Sanofi
Coronary Artery Disease
Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion
The optimal treatment of calcified coronary lesion remained to be elucidated. A Prospective, randomized controlled trial was perform to explore the immediate effect and long-term outcome of rotational atherectomy in patients with…
- Trial name
- NCT01887704
- Testing
- Rotablator, conventional angioplasty, stenting
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Capital Medical University
Acute Coronary Syndrome
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome
To demonstrate that a strategy of fast genetic testing performed in outpatient clinic allows to select adequately one of the 2 antiplatelet treatments approved in the same indication (ACS with PCI - prasugrel 10mg MD or…
- Trial name
- GAMMA (NCT01390974)
- Where
- France
- Volunteers
- 270 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Acute Ischemic Stroke
Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke…
- Trial name
- HOPE-MeVO (NCT07776873)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), Standard medical treatment (SMT)
- Where
- China
- Volunteers
- 616 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Acute Coronary Syndrome
Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation
In view of its safety profile and the results of clinical trials, clopidogrel has become the standard treatment for patients with acute coronary syndrome (ACS) and drug eluting stent(DES) implantation.
- Trial name
- NCT00404053
- Testing
- Clopidogrel
- Sponsor
- Shenyang Northern Hospital
Chronic Kidney Disease
Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study
Higher coronary in-stent thromboses and bleeding complications on anti-platelet agents are more common in Chronic Kidney Disease vs. non-Chronic Kidney Disease patients.
- Trial name
- WiCKDonASA (NCT01768637)
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
Angioplasty, Transluminal, Percutaneous Coronary
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.
- Trial name
- PRECEDE (NCT00938522)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
Asymptomatic, Artery
Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis
Background. Carotid artery stenting (CAS) recently has become an accepted method for treatment of patients with high-grade carotid artery stenosis, who are at an increased risk for surgical carotid endarterectomy (CEA).
- Trial name
- NCT00497094
- Testing
- carotid artery stenting
- Where
- Austria
- Volunteers
- 148 people
- Sponsor
- Vienna General Hospital
Coronary Artery Disease(CAD)
Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization
The purpose of this study is to determine whether Danlou Tablet is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.
- Trial name
- NCT03072082
- Testing
- Danlou Tablet, Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
- Volunteers
- 440 people
- Sponsor
- Jun Li
Platelet Aggregation Onhibitors
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry
The ongoing LAPCOR (Laboratory AntiPlatelet efficacy and Clinical Outcome Registry) registry was initiated in 2008 at a tertiary care cardiac center, and consecutive patients, who underwent intracoronary stent implantation, have…
- Trial name
- LAPCOR (NCT02264912)
- Testing
- antiplatelet drugs - P2Y12 antagonists
- Where
- Czechia
- Volunteers
- 2,016 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Myocardial Infarction, Acute
Cilostazol and Endothelial Progenitor Cell
To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)
- Trial name
- EPISODE (NCT04407312)
- Testing
- Cilostazol Tablets, Aspirin, Clopidogrel
- Volunteers
- 60 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Artery Disease
Clopidogrel and Response Variability Investigation Study 2
To evaluate the role of the genetic variant 2C19*2 on the pharmacodynamic response as assessed by optical aggregometry and on the pharmacokinetic response as assessed by measuring active metabolites following an oral…
- Trial name
- CLOVIS2 (NCT00822666)
- Testing
- clopidogrel
- Where
- France
- Volunteers
- 109 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.